These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22859737)

  • 21. ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth.
    Dai L; Bai A; Smith CD; Rodriguez PC; Yu F; Qin Z
    Mol Cancer Ther; 2017 Dec; 16(12):2724-2734. PubMed ID: 28939554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
    Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
    Front Immunol; 2018; 9():631. PubMed ID: 29643855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase.
    Fitzpatrick LR; Green C; Frauenhoffer EE; French KJ; Zhuang Y; Maines LW; Upson JJ; Paul E; Donahue H; Mosher TJ; Smith CD
    Inflammopharmacology; 2011 Apr; 19(2):75-87. PubMed ID: 20936538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
    Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
    Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis.
    Snider AJ; Ruiz P; Obeid LM; Oates JC
    PLoS One; 2013; 8(1):e53521. PubMed ID: 23301082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.
    Gründker C; Föst C; Fister S; Nolte N; Günthert AR; Emons G
    Breast Cancer Res; 2010; 12(4):R49. PubMed ID: 20630060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.
    Antoon JW; Meacham WD; Bratton MR; Slaughter EM; Rhodes LV; Ashe HB; Wiese TE; Burow ME; Beckman BS
    J Mol Endocrinol; 2011 Jun; 46(3):205-16. PubMed ID: 21321095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice.
    Xia C; Seo YJ; Studstill CJ; Vijayan M; Wolf JJ; Hahm B
    Antiviral Res; 2018 Oct; 158():171-177. PubMed ID: 30125617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sphingosine kinase 2 inhibitor ABC294640 suppresses neuronal excitability and inhibits multiple endogenously and exogenously expressed voltage-gated ion channels in cultured cells.
    Zhang F; Hu W; Qu L; Cang C
    Channels (Austin); 2020 Dec; 14(1):216-230. PubMed ID: 32615066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S100β as a serum marker in endocrine resistant breast cancer.
    Charmsaz S; Hughes É; Bane FT; Tibbitts P; McIlroy M; Byrne C; Cocchiglia S; McBryan J; Hennessy BT; Dwyer RM; Kerin MJ; Hill AD; Young LS
    BMC Med; 2017 Apr; 15(1):79. PubMed ID: 28399921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
    Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
    Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
    Poti F; Bot M; Costa S; Bergonzini V; Maines L; Varga G; Freise H; Robenek H; Simoni M; Nofer JR
    Thromb Haemost; 2012 Mar; 107(3):552-61. PubMed ID: 22234485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients.
    Watson C; Long JS; Orange C; Tannahill CL; Mallon E; McGlynn LM; Pyne S; Pyne NJ; Edwards J
    Am J Pathol; 2010 Nov; 177(5):2205-15. PubMed ID: 20889557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.
    Maines LW; Fitzpatrick LR; Green CL; Zhuang Y; Smith CD
    Inflammopharmacology; 2010 Apr; 18(2):73-85. PubMed ID: 20151210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
    Schubert A; Hawighorst T; Emons G; Gründker C
    Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.